A Prospective, Randomized, Placebo-controlled, Multicenter, International Phase I/II Trial of RAD001 (Everolimus) in Combination With DHAP as Induction Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Phase I primary outcome measure
Peter Borchmann, Prof.
University of Cologne, German Hodgkin Study Group
Germany: Federal Institute for Drugs and Medical Devices